Indivior PLC (INVVY) Research

Indivior PLC, encompassing its various subsidiaries, is a pharmaceutical firm dedicated to the research, production, and global commercialization of prescription medications. These therapies primarily utilize buprenorphine to treat opioid dependence and associated medical conditions. The company's development pipeline is actively exploring novel treatments for opioid use disorder (OUD) and schizophrenia. Its current portfolio features the SUBLOCADE subcutaneous injection, along with sublingual formulations like SUBOXONE film, SUBOXONE tablets, and SUBUTEX tablets. Additionally, Indivior sells established products such as Temgesic, Burpex, and Buprenex. With operations spanning approximately 40 countries worldwide, the company also maintains a research collaboration agreement with Addex Therapeutics Ltd. Indivior PLC was founded in 2014 and is headquartered in North Chesterfield, Virginia.

Market snapshot

Symbol
INVVY
Price
$21.85
Day change
0.00%
Market cap
$4.8B
P/E ratio
19.13x
52-week range
14.76-75.65
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Analyst price target
$50.00

Peer companies

  • Alfresa Holdings Corporation (ARHCF)
  • Ascentage Pharma Group International (ASPHF)
  • Digital Utilities Ventures, Inc. (DUTV)
  • Galenica AG (GALNF)
  • Karo Pharma AB (publ) (KARBF)
  • Mithra Pharmaceuticals S.A. (MITPF)
  • MorphoSys AG (MPSYF)
  • Nihon Kohden Corporation (NHNKF)

Open Indivior PLC (INVVY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.